Zusammenfassung
Nur ein Drittel aller Frauen im Alter über 65 Jahren mit einer Osteoporose erhält eine Therapie; viele erleiden eine Fraktur. Bei Männern ist die Datenlage nicht klar. Mithilfe eines neu erarbeiteten Algorithmus und anhand der aktuellen Leitlinien sind die Diagnose und eine spezifische Therapie einfach zu vorzunehmen. Die Differenzialtherapie ist gemäß dem Nebenwirkungsprofil der spezifischen Medikation individuell zu wählen; die therapeutischen Effekte der spezifischen Osteoporosemedikation sind in den Vergleichsstudien nicht signifikant unterschiedlich. Der vorliegende Beitrag bietet eine aktuelle Übersicht über die derzeit verfügbare medikamentöse und nichtmedikamentöse Therapie und fasst Ansätze für eine verbesserte Kontrolle der Erkrankung mithilfe neuer Medikamente und Interventionen zusammen.
Abstract
Only one third of all women with osteoporosis over the age of 65 years are adequately treated; therefore, many experience fractures. For men the data are insufficient. Using a newly developed algorithm and based on the current guidelines, the diagnosis and specific treatment of osteoporosis can be easily set up. The differential treatment should be selected in an individualized approach based on the side effect profile of the specific medication. No statistically significant differences were found between most specific osteoporotic drugs in head-to-head comparisons. This article presents an overview of the currently available pharmaceutical and non-pharmaceutical forms of treatment as well as approaches with novel medications and interventions for a better control of osteoporosis.
Literatur
Hadji P, Klein S, Gothe H et al (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110(4):52–57
Siris ES, Yu J, Bognar K et al (2015) Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage. Clin Interv Aging 10:1813–1824
Schray D, Neuerburg C, Stein J et al (2016) Value of a coordinated management of osteoporosis via Fracture Liaison Service for the treatment of orthogeriatric patients. Eur J Trauma Emerg Surg 42(5):559–564
Gamboa A, Duaso E, Marimón P et al (2018) Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit. Osteoporos Int. https://doi.org/10.1007/s00198-018-4622-6
Nayak S, Greenspan SL (2018) How Can We Improve Osteoporosis Care: A Systematic Review and Meta-Analysis of the Efficacy of Quality Improvement Strategies for Osteoporosis. J Bone Miner Res. https://doi.org/10.1002/jbmr.3437
Karjalainen JP, Riekkinen O, Töyräs J et al (2012) Multi-site bone ultrasound measurements in elderly women with and without previous hip fractures. Osteoporos Int 23(4):1287–1295
Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392–396
Adler RA (2012) Secondary fracture prevention. Curr Osteoporos Rep 10(1):22–27
Baim S, Leslie WD (2012) Assessment of fracture risk. Curr Osteoporos Rep 10(1):28–41
Gosch M, Stumpf U, Kammerlander C, Böcker W, Heppner HJ, Wicklein S (2018) Management of osteoporosis after fragility fractures. Z Gerontol Geriatr 51(1):113–125
Dovjak P, Föger-Samwald U, Konrad M, Bichler B, Pietschmann P (2014) Secondary confounders of osteoporotic hip fractures in patients admitted to a geriatric acute care department. Z Gerontol Geriatr. https://doi.org/10.1007/s00391-014-0821-8
Adler RA (2012) Laboratory testing for secondary osteoporosis evaluation. Clin Biochem 45(12):894–900
Bogoch ER, Elliot-Gibson V, Wang RY, Josse RG (2012) Secondary causes of osteoporosis in fracture patients. J Orthop Trauma 26(9):e145–152
Bours SP, van Geel TA, Geusens PP et al (2011) Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab 96(5):1360–1367
Prophylaxe DVO Diagnostik und Therapie der Osteoporose. In. https://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf 2017
Langdahl BL, Andersen JD (2018) Treatment of Osteoporosis: Unmet Needs and Emerging Solutions. J Bone Metab 25(3):133–140
Cakir B, Odabasi E, Turan M, Guler S, Kutlu M (2002) Secondary osteoporosis in women. A retrospective analysis. Arch Gynecol Obstet 266(4):214–217
Pietschmann P, Rauner M, Sipos W, Osteoporosis K‑SK (2009) an age-related and gender-specific disease—a mini-review. Gerontology 55(1):3–12
Avenell A, Mak JC, O’Connell D (2014) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 4:CD227
Black DM, Postmenopausal Osteoporosis RCJ (2016) N Engl J Med 374(21):2096–2097
Bolland MJ, Grey A, Reid IR (2015) Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis? Climacteric 18(Suppl 2):22–31
Albert SG, Reddy S (2017) CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS. Endocr Pract 23(7):841–856
Eriksen EF, Lyles KW, Colón-Emeric CS et al (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313
Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg 45(9:1493–1502
Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. (2018) J Bone Miner Res 33(2):190–198
Rachner TD, Hofbauer L, Göbel A, Tsourdi E (2018) Novel therapies in osteoporosis: PTH-related peptide analogues and inhibitors of sclerostin. J Mol Endocrinol. https://doi.org/10.1530/JME-18-0173
Ensrud KE, Osteoporosis CCJ (2017) Ann Intern Med 167(3):ITC17–ITC32
Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28(1):196–205
Tsai JN, Uihlein AV, Burnett-Bowie SM et al (2016) Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab 101(5):2023–2030
Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57
Karjalainen JP, Riekkinen O, Kröger H (2018) Pulse-echo ultrasound method for detection of post-menopausal women with osteoporotic BMD. Osteoporos Int. https://doi.org/10.1007/s00198-018-4408-x
Schousboe JT, Riekkinen O, Karjalainen J (2017) Prediction of hip osteoporosis by DXA using a novel pulse-echo ultrasound device. Osteoporos Int 28(1):85–93
Eccles E, Thompson JD, Roddam H (2018) An evaluation of Fracture Liaison Services in the detection and management of osteoporotic fragility fractures: A narrative review. Radiography (Lond) 24(4):392–395
Gosch M, Druml T, Nicholas JA et al (2015) Fragility non-hip fracture patients are at risk. Arch Orthop Trauma Surg 135(1):69–77
Rachner TD, Khosla S, Osteoporosis HLC (2011) now and the future. Lancet 377(9773):1276–1287
Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. https://doi.org/10.1056/NEJMoa1607948
Lewiecki EM, Dinavahi RV, Lazaretti-Castro M et al (2018) One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. https://doi.org/10.0002/jbmr.3622
Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585–1594
Fares A (2018) Pharmacological and Non-pharmacological Means for Prevention of Fractures among Elderly. Int J Prev Med 9:78
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P. Dovjak gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Dovjak, P. Osteoporosediagnostik und -therapie bei über 65-Jährigen. Z Gerontol Geriat 52, 421–427 (2019). https://doi.org/10.1007/s00391-019-01548-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00391-019-01548-w